Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 4/20 | 0.53 |
| ▸ | CES1 | P23141 | 6/20 | 0.44 |
| ▸ | FAAH | O00519 | 8/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13446139 | 0.98 | CES2 (0.56) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL13446138 | 0.94 | CES2 (0.46) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL12346014 | 0.93 | CES2 (0.47) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL12346017 | 0.92 | CES2 (0.50) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL12346013 | 0.88 | ALDH1A1 (0.41) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL28342787 | 0.84 | NAAA (0.52) | CES2FAAHNAAAEPHX1 | |
| SCHEMBL12346016 | 0.80 | CES2 (0.33) | CES2 | |
| SCHEMBL13446143 | 0.78 | ALDH1A1 (0.37) | CES2CES1FAAHMEN1KMT2A | |
| SCHEMBL2691707 | 0.77 | NAAA (0.48) | CES2CES1FAAHNAAAEPHX1 | |
| SCHEMBL24360972 | 0.76 | NAAA (0.48) | CES2FAAHNAAAEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476473-B2 | Compound, method for preparing the compound and resist composition containing the compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20100055609-A1 | COMPOUND, METHOD FOR PREPARING THE COMPOUND AND RESIST COMPOSITION CONTAINING THE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055609-A1 | COMPOUND, METHOD FOR PREPARING THE COMPOUND AND RESIST COMPOSITION CONTAINING THE COMPOUND | AFF1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AFF4 | CES2 1611/4885CES1 633/4885FAAH 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.